Purpose

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma prior to registration - Node-positive unresectable (TxN1Mx) or metastatic (TxNxM1) based on the following diagnostic workup: - History/physical examination within 45 days prior to registration - CT/magnetic resonance imaging (MRI) of the chest/abdomen/pelvis within 45 days prior to registration - Patients must have IMDC intermediate (1-2 factors) or poor risk disease (>= 3 factors) - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - Patients with measurable disease (node positive or metastatic) as defined by RECIST version 1.1 excluding the primary renal tumor - Patient not recommended for or refused immediate cytoreductive nephrectomy - Candidate for standard of care therapy with either immuno-oncology (IO)-IO or IO-VEGF combination regimen - Primary renal tumor measuring 20 cm or less in anterior to posterior dimension only on axial imaging - Age >= 18 - Karnofsky performance status >= 60 within 45 days prior to registration - Hemoglobin >= 8 g/dL (transfusions are allowed) (within 45 days prior to registration) - Platelet count >= 50,000/mm^3 (within 45 days prior to registration) - Absolute neutrophil count (ANC) >= 1500/mm^3 (within 45 days prior to registration) - Calculated (Calc.) creatinine clearance >= 30 mL/min (within 45 days prior to registration) - Creatinine clearance (CrCl) >= 30 mL/min estimated by Cockcroft-Gault Equation - For African American patients specifically whose renal function is not considered adequate by the formula above, an alternative formula that takes race into account (Chronic Kidney Disease Epidemiology Collaboration CKD-EPI formula) should be used for calculating the related estimated glomerular filtration rate (GFR) with a correction factor for African American race creatinine clearance for trial eligibility, where GFR >= 30 mL/min/1.73m^2 will be considered adequate - Total bilirubin =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) (within 45 days prior to registration) - Aspartate aminotransferase and alanine aminotransferase (AST and ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if hepatic metastases present (within 45 days prior to registration) - Patients with known human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Testing is not required for entry into protocol - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated - Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load - The patient must agree to use a highly effective contraception, including men with vasectomies if they are having sex with a woman of childbearing potential or with a woman who is pregnant, while on study drug and for 6 months following the last dose of study drug. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal - The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria

  • Patients with planned treatment of all metastatic disease with definitive therapy including either surgery, ablative (non-palliative) doses of radiation, or intervention of some type (definitive interventional radiology techniques) to ALL metastatic sites rendering the patient without extra-renal measurable disease. Patients NOT planned for definitive treatment of all metastatic sites are eligible. Lesions radiated palliatively are not eligible for response assessment - Patients with untreated or unstable brain metastases or cranial epidural disease - Note: Patients who have been adequately treated with radiotherapy, radiosurgery, or surgery and stable for at least 4 weeks prior to registration as documented by MRI or CT imaging or deemed stable by clinical investigator are eligible. Treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 4 weeks prior to registration as documented by MRI or CT imaging or deemed stable by clinical investigator - Prior radiotherapy to the kidney that would result in overlap of radiation therapy fields treatment of the primary tumor - Any systemic therapy for metastatic renal cell carcinoma (RCC) that was initiated > 90 days before registration, note that prior chemotherapy for a different cancer is allowed (completed > 3 years prior to registration) - Severe, active comorbidity defined as follows: - Active autoimmune disease requiring ongoing therapy including systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications daily. Inhaled steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease - History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies - Active tuberculosis (purified protein derivative [PPD] response without active tuberculosis [TB] is allowed) - Uncontrolled hypertension (systolic blood pressure [BP] >= 190 mmHg or diastolic BP > 110 mmHg) - Major surgery requiring hospital admission =< 28 days prior to registration - Any serious (requiring hospital stay or long term rehab) non-healing wound, ulcer, or bone fracture within 45 days prior to registration - Any arterial thrombotic (ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], cerebrovascular accident [CVA], etc) events within 180 days prior to registration - Active New York (NY) Heart Association class 3-4 heart failure symptoms - Moderate or severe hepatic impairment (Child-Pugh B or C) - Any history of untreated pulmonary embolism or deep venous thrombosis (DVT) within 180 days prior to registration. (Any asymptomatic or treated pulmonary embolism or asymptomatic treated deep venous thrombosis > 30 days prior to registration is allowed) - Unstable cardiac arrhythmia within 180 days prior to registration - History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel obstruction, or gastric outlet obstruction within 180 days prior to registration - History of or active inflammatory bowel disease - Malabsorption syndrome within 45 days prior to registration - Pregnancy and individuals unwilling to discontinue nursing. For women of child bearing potential must have a negative pregnancy test =< 45 days prior to registration

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Arm I (standard of care immunotherapy)
Patients receive one of the following immunotherapy regimens per physician discretion: nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes every 3 weeks for 4 doses followed by nivolumab IV over 30 minutes every 2 or 4 weeks; pembrolizumab IV over 30 minutes every 3 or 6 weeks and axitinib PO BID; avelumab IV over 60 minutes every 2 weeks and axitinib PO BID; nivolumab IV over 30 minutes every 2 or 4 weeks and cabozantinib PO QD; OR pembrolizumab IV over 30 minutes every 3 or 6 weeks and lenvatinib PO QD. Treatment with immunotherapy continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial.
  • Biological: Avelumab
    Given IV
    Other names:
    • Bavencio
    • MSB 0010718C
    • MSB-0010718C
    • MSB0010718C
  • Drug: Axitinib
    Given PO
    Other names:
    • AG 013736
    • AG-013736
    • AG013736
    • Inlyta
  • Procedure: Biospecimen Collection
    Undergo collection of blood
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Procedure: Bone Scan
    Undergo bone scan
    Other names:
    • Bone Scintigraphy
  • Drug: Cabozantinib
    Given PO
  • Procedure: Computed Tomography
    Undergo CT
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • Computerized Tomography (CT) scan
    • CT
    • CT Scan
    • tomography
  • Biological: Ipilimumab
    Given IV
    Other names:
    • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
    • BMS 734016
    • BMS-734016
    • BMS734016
    • Ipilimumab Biosimilar CS1002
    • MDX 010
    • MDX-010
    • MDX-CTLA4
    • MDX010
    • Yervoy
  • Drug: Lenvatinib
    Given PO
    Other names:
    • E 7080
    • E-7080
    • E7080
    • ER-203492-00
    • Multi-Kinase Inhibitor E7080
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic Resonance Imaging (MRI)
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • MRIs
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
    • sMRI
    • Structural MRI
  • Biological: Nivolumab
    Given IV
    Other names:
    • ABP 206
    • BCD-263
    • BMS 936558
    • BMS-936558
    • BMS936558
    • CMAB819
    • MDX 1106
    • MDX-1106
    • MDX1106
    • NIVO
    • Nivolumab Biosimilar ABP 206
    • Nivolumab Biosimilar BCD-263
    • Nivolumab Biosimilar CMAB819
    • ONO 4538
    • ONO-4538
    • ONO4538
    • Opdivo
  • Biological: Pembrolizumab
    Given IV
    Other names:
    • BCD-201
    • GME 751
    • GME751
    • Keytruda
    • Lambrolizumab
    • MK 3475
    • MK-3475
    • MK3475
    • Pembrolizumab Biosimilar BCD-201
    • Pembrolizumab Biosimilar GME751
    • Pembrolizumab Biosimilar QL2107
    • Pembrolizumab Biosimilar RPH-075
    • Pembrolizumab Biosimilar SB27
    • QL2107
    • RPH 075
    • RPH-075
    • RPH075
    • SB 27
    • SB-27
    • SB27
    • SCH 900475
    • SCH-900475
    • SCH900475
Experimental
Arm II (SABR, standard of care immunotherapy)
Patients undergo SABR on 3 different days over 1-3 weeks and receive immunotherapy as in Arm I. Patients also undergo CT scan or MRI throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial.
  • Biological: Avelumab
    Given IV
    Other names:
    • Bavencio
    • MSB 0010718C
    • MSB-0010718C
    • MSB0010718C
  • Drug: Axitinib
    Given PO
    Other names:
    • AG 013736
    • AG-013736
    • AG013736
    • Inlyta
  • Procedure: Biospecimen Collection
    Undergo collection of blood
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Procedure: Bone Scan
    Undergo bone scan
    Other names:
    • Bone Scintigraphy
  • Drug: Cabozantinib
    Given PO
  • Procedure: Computed Tomography
    Undergo CT
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • Computerized Tomography (CT) scan
    • CT
    • CT Scan
    • tomography
  • Biological: Ipilimumab
    Given IV
    Other names:
    • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
    • BMS 734016
    • BMS-734016
    • BMS734016
    • Ipilimumab Biosimilar CS1002
    • MDX 010
    • MDX-010
    • MDX-CTLA4
    • MDX010
    • Yervoy
  • Drug: Lenvatinib
    Given PO
    Other names:
    • E 7080
    • E-7080
    • E7080
    • ER-203492-00
    • Multi-Kinase Inhibitor E7080
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic Resonance Imaging (MRI)
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • MRIs
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
    • sMRI
    • Structural MRI
  • Biological: Nivolumab
    Given IV
    Other names:
    • ABP 206
    • BCD-263
    • BMS 936558
    • BMS-936558
    • BMS936558
    • CMAB819
    • MDX 1106
    • MDX-1106
    • MDX1106
    • NIVO
    • Nivolumab Biosimilar ABP 206
    • Nivolumab Biosimilar BCD-263
    • Nivolumab Biosimilar CMAB819
    • ONO 4538
    • ONO-4538
    • ONO4538
    • Opdivo
  • Biological: Pembrolizumab
    Given IV
    Other names:
    • BCD-201
    • GME 751
    • GME751
    • Keytruda
    • Lambrolizumab
    • MK 3475
    • MK-3475
    • MK3475
    • Pembrolizumab Biosimilar BCD-201
    • Pembrolizumab Biosimilar GME751
    • Pembrolizumab Biosimilar QL2107
    • Pembrolizumab Biosimilar RPH-075
    • Pembrolizumab Biosimilar SB27
    • QL2107
    • RPH 075
    • RPH-075
    • RPH075
    • SB 27
    • SB-27
    • SB27
    • SCH 900475
    • SCH-900475
    • SCH900475
  • Radiation: Stereotactic Ablative Radiotherapy
    42 Gy in 3 fractions
    Other names:
    • SABER
    • SABR/SBRT

Recruiting Locations

University of Arkansas for Medical Sciences
Little Rock 4119403, Arkansas 4099753 72205
Contact:
Site Public Contact
501-686-8274

PCR Oncology
Arroyo Grande 5324802, California 5332921 93420
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Mills-Peninsula Medical Center
Burlingame 5331920, California 5332921 94010
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

UC San Diego Health System - Encinitas
Encinitas 5346646, California 5332921 92024
Contact:
Site Public Contact
760-536-7700

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine 5359777, California 5332921 92612
Contact:
Site Public Contact
877-827-8839
ucstudy@uci.edu

UC San Diego Moores Cancer Center
La Jolla 5363943, California 5332921 92093
Contact:
Site Public Contact
858-822-5354
cancercto@ucsd.edu

Memorial Medical Center
Modesto 5373900, California 5332921 95355
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange 5379513, California 5332921 92868
Contact:
Site Public Contact
877-827-8839
ucstudy@uci.edu

Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville 5388881, California 5332921 95661
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Roseville Medical Center
Roseville 5388881, California 5332921 95661
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Medical Center Sacramento
Sacramento 5389489, California 5332921 95816
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

UC San Diego Medical Center - Hillcrest
San Diego 5391811, California 5332921 92103
Contact:
Site Public Contact
rhabbaba@health.ucsd.edu

UCSF Medical Center-Mission Bay
San Francisco 5391959, California 5332921 94158
Contact:
Site Public Contact
877-827-3222
cancertrials@ucsf.edu

Mills Health Center
San Mateo 5392423, California 5332921 94401
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Ridley-Tree Cancer Center
Santa Barbara 5392952, California 5332921 93105
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Pacific Medical Foundation
Santa Rosa 5393287, California 5332921 95403
Contact:
Site Public Contact
415-209-2683
clinicalresearch@sutterhealth.org

UCHealth University of Colorado Hospital
Aurora 5412347, Colorado 5417618 80045
Contact:
Site Public Contact
720-848-0650

UCHealth - Cherry Creek
Denver 5419384, Colorado 5417618 80206
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Poudre Valley Hospital
Fort Collins 5577147, Colorado 5417618 80524
Contact:
Site Public Contact
970-297-6150

Cancer Care and Hematology-Fort Collins
Fort Collins 5577147, Colorado 5417618 80528
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UCHealth Greeley Hospital
Greeley 5577592, Colorado 5417618 80631
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UCHealth Highlands Ranch Hospital
Highlands Ranch 5425043, Colorado 5417618 80129
Contact:
Site Public Contact
720-848-0650

UCHealth Lone Tree Health Center
Lone Tree 5429208, Colorado 5417618 80124
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

Medical Center of the Rockies
Loveland 5579368, Colorado 5417618 80538
Contact:
Site Public Contact
970-203-7083

Mount Sinai Comprehensive Cancer Center at Aventura
Aventura 4146429, Florida 4155751 33180
Contact:
Site Public Contact
305-674-2625
yenrique@msmc.com

Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood 4158928, Florida 4155751 33021
Contact:
Site Public Contact
954-265-1847
OHR@mhs.net

Mayo Clinic in Florida
Jacksonville 4160021, Florida 4155751 32224-9980
Contact:
Site Public Contact
855-776-0015

Miami Cancer Institute
Miami 4164138, Florida 4155751 33176
Contact:
Site Public Contact
786-596-2000

Mount Sinai Medical Center
Miami Beach 4164143, Florida 4155751 33140
Contact:
Site Public Contact
305-674-2625
yenrique@msmc.com

Memorial Hospital West
Pembroke Pines 4168139, Florida 4155751 33028
Contact:
Site Public Contact
954-265-4325

Alton Memorial Hospital
Alton 4232679, Illinois 4896861 62002
Contact:
Site Public Contact
618-463-7323

Centralia Oncology Clinic
Centralia 4235587, Illinois 4896861 62801
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern University
Chicago 4887398, Illinois 4896861 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

Carle at The Riverfront
Danville 4889426, Illinois 4896861 61832
Contact:
Site Public Contact
800-446-5532
Research@Carle.com

Cancer Care Specialists of Illinois - Decatur
Decatur 4236895, Illinois 4896861 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Decatur Memorial Hospital
Decatur 4236895, Illinois 4896861 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Kishwaukee
DeKalb 4889553, Illinois 4896861 60115
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Carle Physician Group-Effingham
Effingham 4237727, Illinois 4896861 62401
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Crossroads Cancer Center
Effingham 4237727, Illinois 4896861 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Delnor
Geneva 4893591, Illinois 4896861 60134
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Northwestern Medicine Glenview Outpatient Center
Glenview 4893886, Illinois 4896861 60026
Contact:
Site Public Contact
312-695-1102

Northwestern Medicine Grayslake Outpatient Center
Grayslake 4894465, Illinois 4896861 60030
Contact:
Site Public Contact
312-695-1102

Northwestern Medicine Lake Forest Hospital
Lake Forest 4899012, Illinois 4896861 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

Carle Physician Group-Mattoon/Charleston
Mattoon 4244099, Illinois 4896861 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Cancer Care Center of O'Fallon
O'Fallon 4245926, Illinois 4896861 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

HSHS Saint Elizabeth's Hospital
O'Fallon 4245926, Illinois 4896861 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

UW Health Carbone Cancer Center Rockford
Rockford 4907959, Illinois 4896861 61114
Contact:
Site Public Contact
779-696-9378
lkline@uwhealth.org

Memorial Hospital East
Shiloh 4249910, Illinois 4896861 62269
Contact:
Site Public Contact
314-747-9912
dschwab@wustl.edu

Southern Illinois University School of Medicine
Springfield 4250542, Illinois 4896861 62702
Contact:
Site Public Contact
217-545-7929

Springfield Clinic
Springfield 4250542, Illinois 4896861 62702
Contact:
Site Public Contact
800-444-7541

Springfield Memorial Hospital
Springfield 4250542, Illinois 4896861 62781
Contact:
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Carle Cancer Center
Urbana 4914570, Illinois 4896861 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

The Carle Foundation Hospital
Urbana 4914570, Illinois 4896861 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville 4915525, Illinois 4896861 60555
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Mary Greeley Medical Center
Ames 4846834, Iowa 4862182 50010
Contact:
Site Public Contact
515-956-4132

McFarland Clinic - Ames
Ames 4846834, Iowa 4862182 50010
Contact:
Site Public Contact
515-239-4734
ksoder@mcfarlandclinic.com

UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny 4846960, Iowa 4862182 50023
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive 4852065, Iowa 4862182 50325
Contact:
Site Public Contact
515-241-3305

Iowa Methodist Medical Center
Des Moines 4853828, Iowa 4862182 50309
Contact:
Site Public Contact
515-241-6727

UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines 4853828, Iowa 4862182 50309
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines 4853828, Iowa 4862182 50314
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee 4880981, Iowa 4862182 50263
Contact:
Site Public Contact
515-241-3305

Louisiana Hematology Oncology Associates LLC
Baton Rouge 4315588, Louisiana 4331987 70809
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Mary Bird Perkins Cancer Center
Baton Rouge 4315588, Louisiana 4331987 70809
Contact:
Site Public Contact
225-215-1353
clinicalresearch@marybird.com

Mary Bird Perkins Cancer Center - Metairie
Metairie 4333177, Louisiana 4331987 70002
Contact:
Site Public Contact
504-584-6990

Beverly Hospital
Beverly 4930505, Massachusetts 6254926 01915
Contact:
Site Public Contact
978-922-3000

Massachusetts General Hospital Cancer Center
Boston 4930956, Massachusetts 6254926 02114
Contact:
Site Public Contact
877-726-5130

Brigham and Women's Hospital
Boston 4930956, Massachusetts 6254926 02115
Contact:
Site Public Contact
617-724-5200

Dana-Farber Cancer Institute
Boston 4930956, Massachusetts 6254926 02215
Contact:
Site Public Contact
877-442-3324

Lahey Hospital and Medical Center
Burlington 4931737, Massachusetts 6254926 01805
Contact:
Site Public Contact
781-744-3421
lhmc-cancer-clinical-trials@lahey.org

Addison Gilbert Hospital
Gloucester 4937829, Massachusetts 6254926 01930
Contact:
Site Public Contact
978-283-4000

Lahey Medical Center-Peabody
Peabody 4946863, Massachusetts 6254926 01960
Contact:
Site Public Contact
781-744-3421
lhmc-cancer-clinical-trials@lahey.org

Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor 4984247, Michigan 5001836 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

University of Michigan Comprehensive Cancer Center
Ann Arbor 4984247, Michigan 5001836 48109
Contact:
Site Public Contact
slusserb@med.umich.edu

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton 4986994, Michigan 5001836 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Brighton
Brighton 4986994, Michigan 5001836 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton 4987990, Michigan 5001836 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Canton
Canton 4987990, Michigan 5001836 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Chelsea Hospital
Chelsea 4988628, Michigan 5001836 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea 4988628, Michigan 5001836 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Corewell Health Dearborn Hospital
Dearborn 4990510, Michigan 5001836 48124
Contact:
Site Public Contact
248-551-7695

Corewell Health Farmington Hills Hospital
Farmington Hills 4992523, Michigan 5001836 48336
Contact:
Site Public Contact
248-551-7695

University of Michigan Health - Sparrow Lansing
Lansing 4998830, Michigan 5001836 48912
Contact:
Site Public Contact
517-364-3712
harsha.trivedi@umhsparrow.org

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia 4999837, Michigan 5001836 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Corewell Health William Beaumont University Hospital
Royal Oak 5007804, Michigan 5001836 48073
Contact:
Site Public Contact
248-551-7695

Corewell Health Beaumont Troy Hospital
Troy 5012639, Michigan 5001836 48085
Contact:
Site Public Contact
248-551-7695

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti 5015688, Michigan 5001836 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Sanford Joe Lueken Cancer Center
Bemidji 5017822, Minnesota 5037779 56601
Contact:
Site Public Contact
218-333-5000
OncologyClinicalTrialsFargo@sanfordhealth.org

Essentia Health Saint Joseph's Medical Center
Brainerd 5019116, Minnesota 5037779 56401
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health - Deer River Clinic
Deer River 5024099, Minnesota 5037779 56636
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Cancer Center
Duluth 5024719, Minnesota 5037779 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Saint Mary's Medical Center
Duluth 5024719, Minnesota 5037779 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Miller-Dwan Hospital
Duluth 5024719, Minnesota 5037779 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Fairview Southdale Hospital
Edina 5025264, Minnesota 5037779 55435
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Hibbing Clinic
Hibbing 5030005, Minnesota 5037779 55746
Contact:
Site Public Contact
218-786-3308

Hennepin County Medical Center
Minneapolis 5037649, Minnesota 5037779 55415
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Mayo Clinic in Rochester
Rochester 5043473, Minnesota 5037779 55905
Contact:
Site Public Contact
855-776-0015

Regions Hospital
Saint Paul 5045360, Minnesota 5037779 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Sandstone
Sandstone 5045908, Minnesota 5037779 55072
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Lakeview Hospital
Stillwater 5048814, Minnesota 5037779 55082
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Essentia Health Virginia Clinic
Virginia 5051468, Minnesota 5037779 55792
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Saint Francis Medical Center
Cape Girardeau 4379966, Missouri 4398678 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters 4407237, Missouri 4398678 63376
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia 4381982, Missouri 4398678 65212
Contact:
Site Public Contact
573-882-7440

Siteman Cancer Center at West County Hospital
Creve Coeur 4382837, Missouri 4398678 63141
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Mercy Hospital Springfield
Springfield 4409896, Missouri 4398678 65804
Contact:
Site Public Contact
417-269-4520

Washington University School of Medicine
St Louis 4407066, Missouri 4398678 63110
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Mercy Hospital South
St Louis 4407066, Missouri 4398678 63128
Contact:
Site Public Contact
314-525-6042
Danielle.Werle@mercy.net

Siteman Cancer Center-South County
St Louis 4407066, Missouri 4398678 63129
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center at Christian Hospital
St Louis 4407066, Missouri 4398678 63136
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Mercy Hospital Saint Louis
St Louis 4407066, Missouri 4398678 63141
Contact:
Site Public Contact
314-251-7066

Nebraska Medicine-Bellevue
Bellevue 5063805, Nebraska 5073708 68123
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Nebraska Medicine-Village Pointe
Omaha 5074472, Nebraska 5073708 68118
Contact:
Site Public Contact
402-559-5600

University of Nebraska Medical Center
Omaha 5074472, Nebraska 5073708 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Memorial Sloan Kettering Basking Ridge
Basking Ridge 5095409, New Jersey 5101760 07920
Contact:
Site Public Contact
212-639-7592

Cooper Hospital University Medical Center
Camden 4501018, New Jersey 5101760 08103
Contact:
Site Public Contact
856-325-6757

Monmouth Medical Center Southern Campus
Lakewood 5100280, New Jersey 5101760 08701
Contact:
Site Public Contact
732-923-6564
mary.danish@rwjbh.org

Monmouth Medical Center
Long Branch 5100619, New Jersey 5101760 07740
Contact:
Site Public Contact
732-923-6564
mary.danish@rwjbh.org

Memorial Sloan Kettering Monmouth
Middletown 5101170, New Jersey 5101760 07748
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Bergen
Montvale 5101361, New Jersey 5101760 07645
Contact:
Site Public Contact
212-639-7592

Cooper CyberKnife Center
Mount Laurel 4503136, New Jersey 5101760 08054
Contact:
Site Public Contact
855-632-2667
research-cancer@cooperhealth.edu

Rutgers Cancer Institute of New Jersey
New Brunswick 5101717, New Jersey 5101760 08903
Contact:
Site Public Contact
732-235-7356

Rutgers New Jersey Medical School
Newark 5101798, New Jersey 5101760 07101
Contact:
Site Public Contact
732-235-7356

Community Medical Center
Toms River 4504476, New Jersey 5101760 08755
Contact:
Site Public Contact
732-557-8294
Lennette.Gonzales@rwjbh.org

Lovelace Medical Center-Saint Joseph Square
Albuquerque 5454711, New Mexico 5481136 87102
Contact:
Site Public Contact
505-272-0530
ZPollock@salud.unm.edu

Lovelace Radiation Oncology
Albuquerque 5454711, New Mexico 5481136 87109
Contact:
Site Public Contact
505-272-0530
AYost@nmcca.org

Memorial Sloan Kettering Commack
Commack 5113412, New York 5128638 11725
Contact:
Site Public Contact
212-639-7592

Glens Falls Hospital
Glens Falls 5118693, New York 5128638 12801
Contact:
Site Public Contact
518-926-6700

Memorial Sloan Kettering Westchester
Harrison 5120095, New York 5128638 10604
Contact:
Site Public Contact
212-639-7592

Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York 5128581, New York 5128638 10016
Contact:
Site Public Contact
CancerTrials@nyulangone.org

Memorial Sloan Kettering Cancer Center
New York 5128581, New York 5128638 10065
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Nassau
Uniondale 5141927, New York 5128638 11553
Contact:
Site Public Contact
212-639-7592

UNC Lineberger Comprehensive Cancer Center
Chapel Hill 4460162, North Carolina 4482348 27599
Contact:
Site Public Contact
877-668-0683
cancerclinicaltrials@med.unc.edu

Carolinas Medical Center/Levine Cancer Institute
Charlotte 4460243, North Carolina 4482348 28203
Contact:
Site Public Contact
800-804-9376

Atrium Health Pineville/LCI-Pineville
Charlotte 4460243, North Carolina 4482348 28210
Contact:
Site Public Contact
980-442-2000

Atrium Health University City/LCI-University
Charlotte 4460243, North Carolina 4482348 28262
Contact:
Site Public Contact
800-804-9376

Levine Cancer Institute-Ballantyne
Charlotte 4460243, North Carolina 4482348 28277
Contact:
Site Public Contact
800-804-9376

Wake Forest University at Clemmons
Clemmons 4461015, North Carolina 4482348 27012
Contact:
Site Public Contact
888-716-9259

Atrium Health Cabarrus/LCI-Concord
Concord 4461574, North Carolina 4482348 28025
Contact:
Site Public Contact
800-804-9376

Duke University Medical Center
Durham 4464368, North Carolina 4482348 27710
Contact:
Site Public Contact
888-275-3853

Levine Cancer Institute-Gaston
Gastonia 4467732, North Carolina 4482348 28054
Contact:
Site Public Contact
800-804-9376

Hayworth Cancer Center
High Point 4471025, North Carolina 4482348 27262
Contact:
Site Public Contact
336-802-2500

Atrium Health Union/LCI-Union
Monroe 4479946, North Carolina 4482348 28112
Contact:
Site Public Contact
980-442-2000

Wake Forest Baptist Health - Wilkes Medical Center
Wilkesboro 4499138, North Carolina 4482348 28659
Contact:
Site Public Contact
888-716-9253

Wake Forest University Health Sciences
Winston-Salem 4499612, North Carolina 4482348 27157
Contact:
Site Public Contact
336-713-6771

Sanford Bismarck Medical Center
Bismarck 5688025, North Dakota 5690763 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Broadway Medical Center
Fargo 5059163, North Dakota 5690763 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Roger Maris Cancer Center
Fargo 5059163, North Dakota 5690763 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

UH Seidman Cancer Center at UH Avon Health Center
Avon 5146277, Ohio 5165418 44011
Contact:
Site Public Contact
800-641-2422

UHHS-Chagrin Highlands Medical Center
Beachwood 5146711, Ohio 5165418 44122
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Dayton Physicians LLC-Miami Valley South
Centerville 4508204, Ohio 5165418 45459
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Hospital South
Centerville 4508204, Ohio 5165418 45459
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

University of Cincinnati Cancer Center-UC Medical Center
Cincinnati 4508722, Ohio 5165418 45219
Contact:
Site Public Contact
513-584-7698
cancer@uchealth.com

Case Western Reserve University
Cleveland 5150529, Ohio 5165418 44106
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Ohio State University Comprehensive Cancer Center
Columbus 4509177, Ohio 5165418 43210
Contact:
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Miami Valley Hospital
Dayton 4509884, Ohio 5165418 45409
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Premier Blood and Cancer Center
Dayton 4509884, Ohio 5165418 45409
Contact:
Site Public Contact
937-276-8320

Dayton Physician LLC - Englewood
Dayton 4509884, Ohio 5165418 45415
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Hospital North
Dayton 4509884, Ohio 5165418 45415
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Atrium Medical Center-Middletown Regional Hospital
Franklin 4512203, Ohio 5165418 45005-1066
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Dayton Physicians LLC-Atrium
Franklin 4512203, Ohio 5165418 45005
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Cancer Care and Infusion
Greenville 5156493, Ohio 5165418 45331
Contact:
Site Public Contact
937-569-7515

UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor 5162645, Ohio 5165418 44060
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

University Hospitals Parma Medical Center
Parma 5166177, Ohio 5165418 44129
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

University Hospitals Portage Medical Center
Ravenna 5167737, Ohio 5165418 44266
Contact:
Site Public Contact
800-641-2422
CTUReferral@UHhospitals.org

Upper Valley Medical Center
Troy 5174358, Ohio 5165418 45373
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

University of Cincinnati Cancer Center-West Chester
West Chester 4520522, Ohio 5165418 45069
Contact:
Site Public Contact
513-584-7698
cancer@uchealth.com

University of Oklahoma Health Sciences Center
Oklahoma City 4544349, Oklahoma 4544379 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa 4553433, Oklahoma 4544379 74146
Contact:
Site Public Contact
918-505-3200

Lehigh Valley Hospital-Cedar Crest
Allentown 5178127, Pennsylvania 6254927 18103
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

UPMC-Heritage Valley Health System Beaver
Beaver 5179446, Pennsylvania 6254927 15009
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

Lehigh Valley Hospital - Muhlenberg
Bethlehem 5180225, Pennsylvania 6254927 18017
Contact:
Site Public Contact
610-402-9543
Morgan_M.Horton@lvhn.org

Carlisle Regional Cancer Center
Carlisle 5183234, Pennsylvania 6254927 17015
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Hillman Cancer Center Erie
Erie 5188843, Pennsylvania 6254927 16505
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg 5192029, Pennsylvania 6254927 15601
Contact:
Site Public Contact
724-838-1900

UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg 5192726, Pennsylvania 6254927 17109
Contact:
Site Public Contact
717-724-6765
klitchfield@PINNACLEHEALTH.org

UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg 5200657, Pennsylvania 6254927 17050
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC Hillman Cancer Center - New Castle
New Castle 5203127, Pennsylvania 6254927 16105
Contact:
Site Public Contact
412-389-5208
haneydl@upmc.edu

UPMC-Magee Womens Hospital
Pittsburgh 5206379, Pennsylvania 6254927 15213
Contact:
Site Public Contact
412-647-2811

UPMC-Saint Margaret
Pittsburgh 5206379, Pennsylvania 6254927 15215
Contact:
Site Public Contact
412-784-4900

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh 5206379, Pennsylvania 6254927 15232
Contact:
Site Public Contact
412-647-8073

UPMC-Shadyside Hospital
Pittsburgh 5206379, Pennsylvania 6254927 15232
Contact:
Site Public Contact
412-621-2334

UPMC-Passavant Hospital
Pittsburgh 5206379, Pennsylvania 6254927 15237
Contact:
Site Public Contact
412-367-6454

UPMC-Saint Clair Hospital Cancer Center
Pittsburgh 5206379, Pennsylvania 6254927 15243
Contact:
Site Public Contact
412-502-3920

Reading Hospital
West Reading 5218867, Pennsylvania 6254927 19611
Contact:
Site Public Contact
610-988-9323

Divine Providence Hospital
Williamsport 5219585, Pennsylvania 6254927 17754
Contact:
Site Public Contact
412-339-5294
Roster@nrgoncology.org

UPMC Memorial
York 4562407, Pennsylvania 6254927 17408
Contact:
Site Public Contact
717-724-6760

Medical University of South Carolina
Charleston 4574324, South Carolina 4597040 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Self Regional Healthcare
Greenwood 4580569, South Carolina 4597040 29646
Contact:
Site Public Contact
864-725-4771
nmcgaha@selfregional.org

Sanford Cancer Center Oncology Clinic
Sioux Falls 5231851, South Dakota 5769223 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Parkland Memorial Hospital
Dallas 4684888, Texas 4736286 75235
Contact:
Site Public Contact
214-590-5582
canceranswerline@UTSouthwestern.edu

UT Southwestern Simmons Cancer Center - RedBird
Dallas 4684888, Texas 4736286 75237
Contact:
Site Public Contact
214-648-7097
canceranswerline@utsouthwestern.edu

UT Southwestern/Simmons Cancer Center-Dallas
Dallas 4684888, Texas 4736286 75390
Contact:
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

UT Southwestern/Simmons Cancer Center-Fort Worth
Fort Worth 4691930, Texas 4736286 76104
Contact:
Site Public Contact
214-648-7097
canceranswerline@UTSouthwestern.edu

UT Southwestern Clinical Center at Richardson/Plano
Richardson 4722625, Texas 4736286 75080
Contact:
Site Public Contact
972-669-7044
Suzanne.cole@utsouthwestern.edu

Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners 5233780, Vermont 5242283 05602
Contact:
Site Public Contact
802-225-5400

University of Vermont Medical Center
Burlington 5234372, Vermont 5242283 05401
Contact:
Site Public Contact
802-656-4101
rpo@uvm.edu

University of Vermont and State Agricultural College
Burlington 5234372, Vermont 5242283 05405
Contact:
Site Public Contact
802-656-8990
rpo@uvm.edu

Bon Secours Saint Francis Medical Center
Midlothian 4772943, Virginia 6254928 23114
Contact:
Site Public Contact
804-893-8978
anne_carmellat@bshsi.org

Bon Secours Cancer Institute at Reynolds Crossing
Richmond 4781708, Virginia 6254928 23230
Contact:
Site Public Contact
804-893-8978
Anne_caramella@bshsi.org

Virginia Mason Medical Center
Seattle 5809844, Washington 5815135 98101
Contact:
Site Public Contact
206-287-6275
cancerresearch@virginiamason.org

West Virginia University Charleston Division
Charleston 4801859, West Virginia 4826850 25304
Contact:
Site Public Contact
304-388-9944

Edwards Comprehensive Cancer Center
Huntington 4809537, West Virginia 4826850 25701
Contact:
Site Public Contact
304-399-6566
Christina.Cole@chhi.org

Langlade Hospital and Cancer Center
Antigo 5244010, Wisconsin 5279468 54409
Contact:
Site Public Contact
715-623-9869
Juli.Alford@aspirus.org

Duluth Clinic Ashland
Ashland 5244247, Wisconsin 5279468 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Northwest Wisconsin Cancer Center
Ashland 5244247, Wisconsin 5279468 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Marshfield Medical Center-EC Cancer Center
Eau Claire 5251436, Wisconsin 5279468 54701
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Essentia Health-Hayward Clinic
Hayward 5255882, Wisconsin 5279468 54843
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison 5261457, Wisconsin 5279468 53718
Contact:
Site Public Contact
800-622-8922
clinicaltrials@cancer.wisc.edu

University of Wisconsin Carbone Cancer Center - University Hospital
Madison 5261457, Wisconsin 5279468 53792
Contact:
Site Public Contact
800-622-8922
clinicaltrials@cancer.wisc.edu

Marshfield Medical Center-Marshfield
Marshfield 5261969, Wisconsin 5279468 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Froedtert Menomonee Falls Hospital
Menomonee Falls 5262630, Wisconsin 5279468 53051
Contact:
Site Public Contact
262-257-5100

Medical College of Wisconsin
Milwaukee 5263045, Wisconsin 5279468 53226
Contact:
Site Public Contact
414-805-3666

Marshfield Medical Center - Minocqua
Minocqua 5263156, Wisconsin 5279468 54548
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

ProHealth D N Greenwald Center
Mukwonago 5263965, Wisconsin 5279468 53149
Contact:
Site Public Contact
research.institute@phci.org

Cancer Center of Western Wisconsin
New Richmond 5264475, Wisconsin 5279468 54017
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Drexel Town Square Health Center
Oak Creek 5265228, Wisconsin 5279468 53154
Contact:
Site Public Contact
414-805-0505

ProHealth Oconomowoc Memorial Hospital
Oconomowoc 5265499, Wisconsin 5279468 53066
Contact:
Site Public Contact
262-928-7878

Aspirus Cancer Care - James Beck Cancer Center
Rhinelander 5268720, Wisconsin 5279468 54501
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Marshfield Medical Center-Rice Lake
Rice Lake 5268798, Wisconsin 5279468 54868
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Essentia Health-Spooner Clinic
Spooner 5274034, Wisconsin 5279468 54801
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Aspirus Cancer Care - Stevens Point
Stevens Point 5274644, Wisconsin 5279468 54481
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Marshfield Medical Center-River Region at Stevens Point
Stevens Point 5274644, Wisconsin 5279468 54482
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Essentia Health Saint Mary's Hospital - Superior
Superior 5275191, Wisconsin 5279468 54880
Contact:
Site Public Contact
701-364-6272

UW Cancer Center at ProHealth Care
Waukesha 5278052, Wisconsin 5279468 53188
Contact:
Site Public Contact
262-928-5539
Chanda.miller@phci.org

Aspirus Regional Cancer Center
Wausau 5278120, Wisconsin 5279468 54401
Contact:
Site Public Contact
877-405-6866

Froedtert West Bend Hospital/Kraemer Cancer Center
West Bend 5278422, Wisconsin 5279468 53095
Contact:
Site Public Contact
414-805-0505

Marshfield Medical Center - Weston
Weston 5278693, Wisconsin 5279468 54476
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Contact:
Site Public Contact
715-422-7718

More Details

NCT ID
NCT05327686
Status
Recruiting
Sponsor
NRG Oncology

Detailed Description

PRIMARY OBJECTIVE: I. To determine whether the addition of stereotactic ablative radiotherapy (SABR) to the primary tumor in combination with immunotherapy improves outcomes compared to immunotherapy alone in patients with metastatic, unresected, renal cell carcinoma (RCC). The primary endpoint is nephrectomy and radiographic progression-free survival (nrPFS) with progression determined as per iRECIST criteria. SECONDARY OBJECTIVES: I. To assess the safety, toxicity and tolerability of the two treatment strategies as defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5 in each treatment arm. II. To assess the objective response rate (ORR) by Immune-related Response Evaluation Criteria in Solid Tumors (iRECIST) in each treatment arm. III. Nephrectomy and radiographic progression-free survival excluding nephrectomies that were performed for non-protocol specified indications (nephrectomy and radiographic progression-free survival [nrPFS]2). IV. Radiographic progression-free survival (rPFS). V. To assess overall survival (OS) in each treatment arm. VI. To assess the time to subsequent second-line therapy or death in each treatment arm. VII. To assess the rate of cytoreductive nephrectomy in each treatment arm. VIII. To assess treatment-free survival in patients who discontinue therapy for reason other than radiographic disease progression. IX. To assess the ORR by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and iRECIST in the primary renal mass. EXPLORATORY OBJECTIVES: I. To assess composite nrPFS in the predefined histological subgroups below: Ia. Clear cell versus non-clear cell histology; Ib. International Metastatic RCC database consortium (IMDC) intermediate versus poor risk group; Ic. Systemic treatment with immunotherapy-immunotherapy combination versus immunotherapy-vascular endothelial growth factor (VEGF) targeted therapy combination; Id. Sarcomatoid versus non sarcomatoid variant. II. To identify prognostic and predictive biomarkers of response to SABR in the context of immunotherapy based treatment via assessment of tissue and blood based biomarkers. III. To evaluate the abscopal effect of SABR with systemic therapy. IIIa. Compare ORR in non-irradiated target lesions in the control arm patients undergoing immunotherapy alone to the experimental arm undergoing SABR + immunotherapy. IV. To evaluate the impact of treatment on level of inferior vena cava (IVC) thrombus. V. To compare accruing center identified iRECIST progression and centrally identified iRECIST progression events on computed tomography (CT). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive one of the following immunotherapy regimens per physician discretion: nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes every 3 weeks for 4 doses followed by nivolumab IV over 30 minutes every 2 or 4 weeks; pembrolizumab IV over 30 minutes every 3 or 6 weeks and axitinib orally (PO) twice daily (BID); avelumab IV over 60 minutes every 2 weeks and axitinib PO BID; nivolumab IV over 30 minutes every 2 or 4 weeks and cabozantinib PO once daily (QD); OR pembrolizumab IV over 30 minutes every 3 or 6 weeks and lenvatinib PO QD. Treatment with immunotherapy continues in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial. ARM II: Patients undergo SABR on 3 different days over 1-3 weeks and receive immunotherapy as in Arm I. Patients also undergo CT scan or MRI throughout the trial. Patients may also undergo a bone scan as clinically indicated and blood sample collection throughout the trial. After completion of study treatment, patients are followed up every 6 months for 5 years, and then annually for 3 years.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.